IMCLE Financials 07/16/2014 02:36:45 Immunoclin C

IMCLE Financials 07/16/2014 02:36:45
Immunoclin Corporation
Period Ending Jan 31, 2014 Feb 28, 2013 Jan 31, 2013 Feb 29, 2012
Total Revenue - 183 183 -
Cost of Revenue - - - -
Gross Profit - 183 183 -
Operating Expenses
Research and Development 98 93 93 -
Sales, General and Admin. 12,676 232 232 85
Non-Recurring Items - - - -
Other 208 2 2 -
Operating Income (12,982) (144) (144) (85)
Income From Continuing Operations
Add'l Income/Expense Items 2 76 76 -
Earnings Before Interest and Tax (12,980) (68) (68) (85)
Interest Expense - - - -
Earnings Before Tax (12,980) (68) (68) (85)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (12,980) (68) (68) (85)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (12,980) (68) (68) (85)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (12,980) (68) (68) (85)